Rheumatol Ther. 2023 doi 10.1007/s40744-023-00583-9 Epub ahead of print
This study by Tanaka, et al. shows that filgotinib reduces peripheral protein biomarkers associated with JAK/STAT signalling, inflammatory signalling, immune cell migration, and bone resorption in RA patients. Notably, filgotinib 200 mg significantly reduced IL-6, TNF, CXCL13 levels as early as Week 4.
Data were taken from FINCH1, a global, Phase 3, double-blind, active-controlled study. Biomarkers were analysed at baseline, Week 4, and Week 12. Patients were randomised to filgotinib 100 mg, filgotinib 200 mg, adalimumab 40 mg, or placebo.